Nektar Therapeutics (NKTR) Profit After Tax Growth (3y) (2013 - 2026)

Nektar Therapeutics (NKTR) Profit After Tax Growth (3y) (2013 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) PAT Growth (3y) (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 38.43%
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn 13.80%
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn -27.65%
7 Belite Bio 61.40 Bn 61.40 Bn - -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn 86.98%
9 Revolution Medicines 37.37 Bn 37.37 Bn - -
10 Nektar Therapeutics 1.76 Bn 1.19 Bn 3.16 Mn 30.85%

Historic Data

Download Data
DateValue
Mar 31, 2026 30.85%
Dec 31, 2025 15.45%
Sep 30, 2025 15.58%
Jun 30, 2025 36.25%
Mar 31, 2025 18.14%
Dec 31, 2024 27.03%
Sep 30, 2024 34.14%
Jun 30, 2024 25.29%
Mar 31, 2024 32.97%
Dec 31, 2023 28.93%
Sep 30, 2023 24.99%
Jun 30, 2023 13.44%
Mar 31, 2023 0.69%
Dec 31, 2022 18.96%
Sep 30, 2022 15.71%
Jun 30, 2022 -13.38%
Mar 31, 2022 8.13%
Dec 31, 2021 -14.04%
Sep 30, 2021 -10.50%
Jun 30, 2021 -28.65%